Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7593748 | 0.84 | L3MBTL1 (0.71) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4058549 | 0.82 | MAPK1 (0.49) | L3MBTL1SIGMAR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL2148591 | 0.80 | SIGMAR1 (0.56) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8332997 | 0.78 | SIGMAR1 (0.55) | L3MBTL1SIGMAR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1116302 | 0.76 | L3MBTL1 (0.61) | L3MBTL1SIGMAR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9082911 | 0.76 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1116321 | 0.76 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2357864 | 0.74 | L3MBTL1 (1.00) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL194142 | 0.74 | ALDH1A1 (0.66) | L3MBTL1SIGMAR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL10665419 | 0.74 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877908-B2 | Stimulus-responsive apta chelamers | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-11-04 | — | — | US | disclosed |
| US-20110190483-A1 | Stimulus-Responsive Apta Chelamers | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010006238-A2 | STIMULUS-RESPONSIVE APTA-CHELAMERS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20070110752-A1 | Fibroblast growth factor receptors and methods for their use | GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED (NZ) | 2007-05-17 | — | — | US | disclosed |
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2006135263-A1 | FIBROBLAST GROWTH FACTOR RECEPTOR-5 ANTIBODIES AND METHODS FOR THEIR USE | GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED (NZ) | 2006-12-21 | — | — | WO | disclosed |
| US-20060115483-A1 | Receptor polypeptide and polynucleotide encoding polypeptide; anticancer agents; viricides; multiple sclerosis; antiarthritic agents; cardiovascular disorders; osteoporosis | GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED (NZ) | 2006-06-01 | — | — | US | disclosed |
| US-20050112642-A1 | Fibroblast growth factor receptors and methods for their use | GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED (NZ) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | L3MBTL1 3309/4885SIGMAR1 125/4885GRIN2D 304/4885 |
| US-20110190483-A1 | Stimulus-Responsive Apta Chelamers | CNBP, CREB1, ATF4 | L3MBTL1 1495/4885SIGMAR1 3412/4885GRIN2D 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.